Skip to Content
  • Review
  • Open Access

18 November 2026

51 Pages

PCSK9 Inhibition in Transition: From Established Treatments to Emerging Therapeutic Approaches

,
,
and
Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
*
Author to whom correspondence should be addressed.

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted proprotein convertase that promotes lysosomal degradation of the hepatic low-density lipoprotein receptor (LDLR), thereby reducing the clearance of circulating low-density lipoprotein cholesterol (LDL-C). Its validation as a therapeutic target is supported by human genetic evidence demonstrating that loss-of-function variants are associated with lifelong reductions in LDL-C and protection against cardiovascular disease. This review examines the biology of PCSK9 and the expanding range of strategies for its pharmacological inhibition, integrating evidence from human genetic studies, clinical trials, and preclinical models, with particular emphasis on translational relevance. The monoclonal antibodies evolocumab and alirocumab substantially reduce LDL-C levels and cardiovascular risk, whereas inclisiran, a small interfering RNA (siRNA), achieves sustained suppression of hepatic PCSK9 synthesis with infrequent dosing. Recent therapeutic advances include the FDA approvals of lerodalcibep, a third-generation injectable PCSK9 inhibitor, and enlicitide decanoate, an orally administered macrocyclic peptide inhibitor. In parallel, nanoparticle-based delivery systems, active PCSK9 vaccination, and CRISPR-based genome editing represent emerging therapeutic strategies that remain largely in preclinical development. Beyond cardiovascular disease, PCSK9 has been implicated in sepsis, cancer, and neurodegenerative, pulmonary, and autoimmune disorders, although the supporting evidence remains heterogeneous and predominantly preclinical. In oncology, experimental findings implicating PCSK9 in tumor immune evasion and modulation of responses to immune checkpoint blockade have prompted its clinical evaluation as a potential adjunct to anticancer therapy. Further prospective clinical studies are required to establish the efficacy and long-term safety of novel PCSK9-targeted approaches and determine whether their therapeutic potential translates into meaningful clinical benefits.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.